31results about How to "Reduce the degree of edema" patented technology

The invention discloses a formula of traditional Chinese medicines for treating soft tissue injury and a method for preparing a preparation thereof. The formula comprises the following six traditional Chinese medicines in parts by weight according to mixture ratio: 3-9 parts of ceratostigma willmottianum, 1-5 parts of hyacinth bletilla, 1-5 parts of Gaultheria yunnanensis, 0.1-0.5 part of dragon's blood, 0.5-2 parts of turpentine and 0.3-2 parts of borneol which are prepared into an externally-applied traditional Chinese medicine preparation. The prepared externally-applied traditional Chinese medicine preparation is a spraying agent, a tincture, a liniment or a film coating agent. The result of experiments shows that the invention has the advantages of no irritability, no hypersensitivity, quick acting of the medicines, obvious effects of promoting the restoration of the injured soft tissues, resisting inflammation and relieving pain and the like. The preparation prepared by the invention enriches the active components of the medicines highly, has convenient carrying and use and accurate use dose and overcomes the defects of low content of effective components, difficult quality control, poor stability and the like.

The invention provides tissue-engineered corneal endothelium constructed in vitro and a preparation method thereof. The preparation method comprises the following steps: preparation of an ultrathin acellular porcine corneal posterior matrix; culture; induction of human multi-potent stem cells; construction of the tissue-engineered corneal endothelium; etc. According to the invention, the ultrathin acellular porcine corneal posterior matrix containing the Descemet's membrane is prepared and human multi-potent stem cell-derived corneal endothelial cells are cooperatively used for in-vitro construction of the tissue-engineered corneal endothelium; so problems in sources of cornea donors are overcome, and the problem that tissue-engineered corneas are too thick for clinical treatment is overcome.

The invention relates to a sterile zinc-based montmorillonite Band-Aid as well as a preparation method and an application thereof. The Band-Aid comprises base cloth, an inner pad and a bonding part, wherein a medicament is attached to the inner pad. The Band-Aid is characterized in that the medicament contains zinc-based montmorillonite. Free zinc ions and montmorillonite can be dissociated from the used zinc-based montmorillonite, the medicament side of the Band-Aid is pasted to a skin wound, and the montmorillonite dissociated from the zinc-based montmorillonite of the Band-Aid can form gel after encountering blood, so that bleeding is stopped quickly; the formed gel can be used as a protection layer on the surface and the periphery of the wound to prevent external bacteria from invading; the zinc ions dissociated from the zinc-based montmorillonite have antibacterial and anti-inflammatory effects and has astringent and healing effects on damaged skin.

The invention relates to a medicine for preventing and treating ischemic stroke. In the mouse cerebral ischemia-reperfusion model, the compound of the present invention can significantly reduce the behavioral score, can significantly reduce the percentage of cerebral infarction / whole brain, and can significantly reduce the water content of ischemia-reperfusion damaged brain tissue, and relieve ischemia. The degree of lateral cerebral hemisphere edema can be used to prevent and treat ischemic stroke.

The invention relates to compound montmorillonite lysozyme powder for treating skin ulcer, a preparation method and application thereof. The compound montmorillonite lysozyme powder is prepared from the following raw materials in parts by weight: 50-120 parts of montmorillonite, 5-10 parts of lysozyme, and 20-50 parts of hydroxy propyl cellulose. According to the invention, the montmorillonite and the lysozyme are used as the effective components and the pharmaceutic adjuvant of the compound montmorillonite lysozyme powder disclosed by the invention; and the compound montmorillonite lysozyme powder is prepared into a drug through the processes, such as a montmorillonite dry heat sterilization process, a lysozyme ultraviolet sterilization process and a hydroxy propyl cellulose ethylene oxide process. The invention further provides application of the preparation in preparation of a drug for treating skin ulcer. Due to drug delivery for skin external use, the compound montmorillonite lysozyme powder has better effects on skin ulcer in different periods.

The invention belongs to the technical field of traditional Chinese medicine fermentation, and provides astragalus membranaceus fermentation liquor as well as a preparation method and application thereof. The preparation process comprises the following steps of soaking astragalus membranaceus slices in water, decocting, and filtering to obtain medicine residues and first medicine liquid, adding water into the medicine residues, and decocting to obtain second medicine liquid, combining the first medicine liquid and the second medicine liquid, and concentrating to obtain an astragalus membranaceus water extract, mixing lactobacillus plantarum LZU-S-ZCJ with LZU-J-TSL6, and inoculating the mixture into the astragalus membranaceus water extract for fermentation, so as to obtain the astragalus membranaceus fermentation liquor. The astragalus membranaceus fermentation liquor obtained by the method disclosed by the invention can relieve the edema degree of mouse lungs, relieve the inflammatory cell infiltration state caused by lipopolysaccharide (LPS), reduce the accumulation of protein liquid in the mouse lungs, reduce the concentration of inflammatory factors in BALF of mice with acute lung injury, regulate the frontal intestinal flora of the mice with acute lung injury and the like, can be used for treating acute lung injury, and has a good effect of relieving mouse acute lung injury.

The invention discloses a pharmaceutical composition for treating acute lung injury and belongs to the technical field of biopharmaceutical industry. The pharmaceutical composition comprises the following main components in parts by weight: 20-25 parts of puerarin, 0.2-0.4 part of verapamil, 1-2 parts of ulinastatin, 0.6-0.8 part of an NE inhibitor, 0.3-0.6 part of a salviae miltiorrhizae water extract and 0.4-0.8 part of glutamine. The invention provides the pharmaceutical composition for treating acute lung injury. By means of matched use of puerarin and verapamil, the pharmaceutical composition can effectively treat acute lung injury and inhibit rise of content of blood serum TNF-alpha, alleviate PMN infiltration, eliminate free radicals and alleviate the extent of lung tissue edema, and has an effective protecting action on acute lung injury; and moreover, the oxygenation index of arterial partial pressure of oxygen is obviously increased, and the respiratory function of a patient is improved. The pharmaceutical composition disclosed by the invention not only can treat acute lung injury effectively, but also plays a maintaining role on lungs, and is convenient to use and low in cost.

The invention relates to an application of zinc-based montmorillonite and calcium-based montmorillonite sterile styptic powder in preparation of medicines for healing skin wounds. The zinc-based montmorillonite and calcium-based montmorillonite sterile styptic powder is prepared from the following raw materials in parts by mass: 5-10 parts of zinc-based montmorillonite and 8-12 parts of calcium-based montmorillonite. According to the invention, zinc-based montmorillonite and calcium-based montmorillonite are used as effective ingredients of the medicament provided by the invention, and the effective ingredients are combined with pharmaceutical auxiliary materials to be prepared into the medicament through the processes of high-temperature dry heat sterilization, mixing, sterile sub-packaging and the like. Through skin external administration, the medicament can be used for quickly coagulating blood and arresting bleeding as well as preventing wound infection, has anti-bacterial and anti-inflammatory effects, and has converging and healing effects on the injured skin.

The invention provides a diseased limb edema prevention and elimination device, an auxiliary movement system and a working method, and relates to the field of medical instruments. The diseased limb edema prevention and elimination device comprises a flexible sleeve with an electric heating mechanism; the sleeve is matched with a support; the support is rotationally matched with a winding drum parallel to an outer wall generatrix of the sleeve; the winding drum and the sleeve are jointly matched with a binding belt; one end of the binding belt is fixed to the outer side face of the sleeve, andthe other end of the binding belt is wound around the sleeve and then wound around the winding drum; and the winding drum is used for tightening or loosening the part, wound around the winding drum, of the binding belt through rotation. The binding belt applies pressure to an affected limb or reduces the pressure applied to the affected limb through the sleeve by tightening or loosening the part,wound around the winding drum, of the binding belt; the affected limb is subjected to hot compress through an electric heating mechanism, so that the body temperature of the edema position of the affected limb is improved, and detumescence of the affected limb is promoted; and the binding belt is arranged to pressurize the affected limb when the affected limb is subjected to edema preliminarily, and the edema degree is reduced through external pressure, so that continuous expansion of the edema position is effectively prevented, and the detumescence recovery period is shortened.

The invention relates to effect of azadirachtin on preparation of a medicament for promoting survival of an ischemic ultralong random skin flap. An oral administration mode is adopted in the process of promoting survival of the ischemic random skin flap; a using method is that an oral administration dosage per day is 100mg / kg or 200mg / kg and one treatment course includes 5 to 7 days; and by a great amount of animal experiments, a conclusion is obtained that by using the azadirachtin, a survival area ratio of the ultralong random skin flap can be obviously increased, inflammations are reduced,oxidation resistance is improved, a blood vessel density is greatly promoted, and survival of the ischemic random skin flap can be well promoted.

The invention relates to an effect of apigenin in preparation of a medicine for promoting survival of ischemic random flap. An oral administration mode is adopted in the process of promoting the survival of the ischemic random flap; a use method is as follows: the daily oral dosage is 20 mg / kg or 50 mg / kg, and 5-7 days are taken as a course of treatment; and a conclusion is drawn through a large number of animal experiments, and by using the apigenin, the survival area ratio of the super-long random flap can be obviously increased, inflammation is reduced, the oxidation resistance is improved,the vascular density is greatly increased, and the survival of the ischemic random flap can be well promoted.

The invention relates to the application of tilorone in preparing a medicine for reducing hemorrhagic stroke cerebral edema. Experiments show that the tilorone remarkably upregulates an IFN-related gene in mouse brain. In a collagenase-induced cerebral hemorrhage model, the tilorone obviously reduces the cerebral edema degree of a model mouse. Therefore, the types of application diseases of the tilorone are further enlarged, and new medicine selection is also provided for preventing and treating the cerebral edema of hemorrhagic stroke patients.

The invention discloses compound montmorillonite lysozyme ointment for treating skin ulcers and a preparation method and application thereof. The ointment is made of, by mass, 50-120 parts of montmorillonite, 5-10 parts of lysozyme, 5-10 parts of polyethylene glycol 4000, 2-6 parts of glycerin, 3-8 parts of sorbitol and 80-164 parts of sterile water. According to the compound montmorillonite lysozyme ointment, montmorillonite and lysozyme are used as the effective constituents of the ointment and are made to the medicament with pharmaceutic adjuvant through the technologies of dissolution, high-temperature sterilization, filter membrane filtration sterilization, low-speed homogenizing, high-speed homogenizing, stirring, cooling, sterile filling and the like. The invention further provides application of the preparations for preparing medicines for treating skin ulcers. External used medicines are delivered for skin, and the ointment has good effects for treatment of skin ulcers at different times.

The invention relates to a spiro compound used for treating cerebral apoplexy. Shown by a test result, the compound can remarkably improve nerve injury caused by ischemia reperfusion of rice undergoing ischemia reperfusion, can remarkably reduce the cerebral infarction percentage and relieve the edema degree of brain tissue of the rice and can lower the water content. Therefore, the compound has an excellent treatment effect for cerebral apoplexy, especially cerebral arterial thrombosis.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a phlegm-eliminating and dampness-eliminating pharmaceutical composition and application thereof. The phlegm-eliminating and dampness-eliminating pharmaceutical composition is prepared from the following raw material components in parts by mass: 15-30 parts of fructus trichosanthis, 9-30 parts of allium macrostemon, 9-15 parts of rhizoma pinellinae praeparata, 9-30 parts of codonopsis pilosula, 6-15 parts of curcuma zedoary and 2-6 parts of coptis chinensis. A coronary heart disease damp syndrome mouse model experiment shows that the phlegm eliminating and dampness eliminating formula can remarkably improve ST segment and T wave pressure of a coronary heart disease damp syndrome mouse, inhibit myocardial hypertrophy of the coronary heart disease damp syndrome mouse, reduce leakage of myocardial injury zymogram of CK-MB, cTnT, LDH and oxLDL, protect myocardial tissue of ischemia injury, reduce cardiac enlargement caused by isoprenaline, reduce cardiomyopathy change caused by isoprenaline treatment, keep more myocardial cell structures normal, reduce inflammatory cell infiltration, stabilize membrane structures and reduce edema degree, thereby having a better treatment effect on ischemic heart disease or angina pectoris.

The invention relates to the application of tilorone in preparing a medicine for reducing hemorrhagic stroke cerebral edema. Experiments show that the tilorone remarkably upregulates an IFN-related gene in mouse brain. In a collagenase-induced cerebral hemorrhage model, the tilorone obviously reduces the cerebral edema degree of a model mouse. Therefore, the types of application diseases of the tilorone are further enlarged, and new medicine selection is also provided for preventing and treating the cerebral edema of hemorrhagic stroke patients.

The invention discloses application of a calycosin derivative in preparing a medicine for treating cerebral ischemia reperfusion injury. Through experiments, an applicant discovers that the calycosin derivative can up-regulate expression levels of ERalpha and GPR30, and can be more beneficial to reducing a neurological function score, reducing a cerebral infarction volume and reducing a cerebral oedema degree compared with calycosin; the calycosin derivative can dose-dependently up-regulate an ERK1 / 2 and Akt phosphorylation level, and plays a role in protecting an ischemia reperfusion injury nerve cell. The calycosin derivative has a structure as shown in the formula (I) which is shown in the description.

The invention relates to the technical field of medicines, in particular to novel application of nicotinic glycoside (kaempferol-3-O-rutinoside) or analogues thereof in preparation of medicines for preventing and treating traumatic brain injury. The compound has an obvious protection effect on traumatic brain injury of rats, can obviously relieve the encephaledema degree of the rats after injury, improves the behavioral functions after injury, and can improve movement and cognitive impairment and the like within a period of time after injury. Therefore, the compounds represented by nicotinic glycoside can be used for preparing medicines for preventing and treating traumatic brain injury.

The invention relates to a dressing with a fat liquefaction wound healing function and a preparation method of the dressing. The preparation method comprises the following steps that S1, a polyvinyl alcohol medical biomaterial is taken as a raw material to produce a sponge dressing; S2, the sponge dressing is compressed to form micro-negative pressure during imbibition; S3, holes are uniformly punched in the compressed sponge dressing, and the dressing with the fat liquefaction wound healing function is finally obtained. The functional dressing adopts the polyvinyl alcohol medical biomaterialas the raw material, and is a polymer material having excellent imbibition performance and a very soft surface when being in contact with the human body and being capable of being completely naturallydegraded. In addition, the functional dressing is convenient to use, can quickly perform drainage when being used, has a large imbibition amount, can promote quick healing of wounds, and reduces therisks of secondary pollution; the dressing does not need to be replaced for a long time, thereby reducing the frequency of dressing change, reducing the pain of a patient, and reducing the workload ofa medical worker.

The invention relates to an application of zinc-based montmorillonite and calcium-based montmorillonite sterile styptic powder in preparation of medicines for healing skin wounds. The zinc-based montmorillonite and calcium-based montmorillonite sterile styptic powder is prepared from the following raw materials in parts by mass: 5-10 parts of zinc-based montmorillonite and 8-12 parts of calcium-based montmorillonite. According to the invention, zinc-based montmorillonite and calcium-based montmorillonite are used as effective ingredients of the medicament provided by the invention, and the effective ingredients are combined with pharmaceutical auxiliary materials to be prepared into the medicament through the processes of high-temperature dry heat sterilization, mixing, sterile sub-packaging and the like. Through skin external administration, the medicament can be used for quickly coagulating blood and arresting bleeding as well as preventing wound infection, has anti-bacterial and anti-inflammatory effects, and has converging and healing effects on the injured skin.

The invention discloses a formula of traditional Chinese medicines for treating soft tissue injury and a method for preparing a preparation thereof. The formula comprises the following six traditional Chinese medicines in parts by weight according to mixture ratio: 3-9 parts of ceratostigma willmottianum, 1-5 parts of hyacinth bletilla, 1-5 parts of Gaultheria yunnanensis, 0.1-0.5 part of dragon's blood, 0.5-2 parts of turpentine and 0.3-2 parts of borneol which are prepared into an externally-applied traditional Chinese medicine preparation. The prepared externally-applied traditional Chinese medicine preparation is a spraying agent, a tincture, a liniment or a film coating agent. The result of experiments shows that the invention has the advantages of no irritability, no hypersensitivity, quick acting of the medicines, obvious effects of promoting the restoration of the injured soft tissues, resisting inflammation and relieving pain and the like. The preparation prepared by the invention enriches the active components of the medicines highly, has convenient carrying and use and accurate use dose and overcomes the defects of low content of effective components, difficult quality control, poor stability and the like.

The invention relates to a zinc-based montmorillonite aseptic band-aid and its preparation method and application. The band-aid includes a base cloth, an inner pad and an adhesive part, and a medicament is attached to the inner pad. It is characterized in that the medicament contains zinc base montmorillonite. The zinc-based montmorillonite used in the present invention can dissociate free zinc ions and montmorillonite, and the medicament surface of the band-aid is pasted on the skin wound, and the montmorillonite dissociated from the zinc-based montmorillonite in the band-aid meets After the blood is absorbed, a gel will be formed to stop the bleeding quickly; the formed gel can be used as a protective layer on the surface of the wound and around it to prevent the invasion of external bacteria; the zinc ions dissociated from zinc-based montmorillonite have antibacterial and anti-inflammatory effects, It also has astringent and healing effects on damaged skin.

The present disclosure provides a device for preventing and eliminating edema of an affected limb, an auxiliary motion system, and a working method, which relate to the field of medical equipment, and include a flexible sleeve with an electric heating mechanism, the sleeve is matched with a bracket, and the bracket is rotatably matched with a parallel sleeve parallel to the sleeve. The reel of the busbar on the outer wall of the cylinder, the reel and the sleeve are jointly equipped with a restraint belt. One end of the restraint belt is fixed on the outer side of the sleeve, and the other end is wound around the sleeve and then wound on the reel. The reel is used to tighten or tighten by rotating. Loosen the part where the restraint belt is wound on the reel, and by tightening or loosening the part of the restraint belt wound on the reel, the restraint belt can exert pressure on the affected limb or reduce the pressure on the affected limb through the sleeve, and use the electric heating mechanism to treat the affected limb. Apply hot compress on the limb to increase the body temperature of the edema of the affected limb and promote the swelling of the affected limb; configure a restraint belt to pressurize the affected limb when the limb is initially edema, and reduce the degree of edema through external pressure, thereby effectively preventing the edema from continuing. Extends and shortens the recovery period for swelling.

The invention discloses application of white mulberry root bark fatty oil components to preparation of a drug for treating acute lung injuries. According to the application, research on the effect of the white mulberry root bark fatty oil components on the acute lung injuries of a lipopolysaccharide induced mouse finds that the white mulberry root bark fatty oil components can lower the lung wet weight / dry weight specific value, has the effect of alleviating pulmonary edema and can remarkably reduce the content of proinflammatory factors such as TNF-alpha, IL-1beta and IL-6, it is shown under a light microscope that the white mulberry root bark fatty oil components can relieve all lung tissue pathological changes, and the lung tissue structure tends to be normal. It is indicated that the white mulberry root bark fatty oil components can alleviate pathological injuries by reducing the edema degree of LPS-caused ALI, lower the content of the proinflammatory factors such as TNF-alpha, IL-1beta and IL-6 and achieve a protection effect on LPS-caused ALI, and the mechanism of the components is worthy of further studying.

The invention belongs to the field of traditional Chinese medicine, and in particular relates to a medicinal composition for removing phlegm and removing dampness and application thereof. The pharmaceutical composition for removing phlegm and dehumidification of the present invention is prepared from the following raw material components in parts by mass: 15-30 parts of whole melon, 9-30 parts of Xiebai, 9-15 parts of Pinellia fragrans, 9-30 parts of Codonopsis Radix, and Curcuma 6‑15 servings, Coptis 2‑6 servings. Experiments on a mouse model of coronary heart disease with dampness syndrome show that the Huatan and dampness formula of the present invention can significantly improve ST segment and T wave depression in coronary heart disease phlegm damp syndrome mice, inhibit myocardial hypertrophy in coronary heart disease phlegm damp syndrome mice, and reduce CK-MB Leakage of myocardial injury enzyme spectrum of cTnT, LDH, oxLDL, protect myocardial tissue from ischemic injury, reduce cardiac enlargement caused by isoproterenol, reduce myocardial pathological changes caused by isoproterenol treatment, and maintain more myocardial cells The structure is normal, the infiltration of inflammatory cells is reduced, the membrane structure is stabilized, and the degree of edema is reduced, suggesting that the Hutanquushi Formula of the present invention has a better therapeutic effect on ischemic heart disease or angina pectoris.

The invention discloses application of a calycosin derivative in preparing a medicine for treating cerebral ischemia reperfusion injury. Through experiments, an applicant discovers that the calycosin derivative can up-regulate expression levels of ERalpha and GPR30, and can be more beneficial to reducing a neurological function score, reducing a cerebral infarction volume and reducing a cerebral oedema degree compared with calycosin; the calycosin derivative can dose-dependently up-regulate an ERK1 / 2 and Akt phosphorylation level, and plays a role in protecting an ischemia reperfusion injury nerve cell. The calycosin derivative has a structure as shown in the formula (I) which is shown in the description.